bit.bio joins Ginkgo Bioworks’ Technology Network to enhance R&D capabilities. Their ioCells, crafted with precision reprogramming technology, integrate seamlessly into Ginkgo’s platform. The partnership aims to provide customers with physiologically relevant human cell models, improving research accuracy and accelerating therapeutic development from early discovery to clinical trials, ultimately delivering lifesaving treatments.
bit.bio has been named as the inaugural partner of Ginkgo Bioworks’ groundbreaking Ginkgo Technology Network, a collaboration aimed at providing integrated capabilities for advancing customer R&D programs. bit.bio, known for coding human cells for innovative therapies, joins forces with Ginkgo Bioworks, a leader in cell programming and biosecurity.
As part of this partnership, bit.bio’s ioCells portfolio of precision-reprogrammed human cells for research and drug discovery will integrate seamlessly into Ginkgo’s platform ecosystem. These ioCells, crafted using bit.bio’s opti-ox™ technology, offer defined human cells with unmatched scalability, consistency, and ease of handling and cultivation.
Jason Kelly, CEO and co-founder of Ginkgo Bioworks, expressed enthusiasm for the partnership, highlighting how bit.bio’s ioCells will empower customers to conduct research and drug development using physiologically relevant human cell models across Ginkgo’s ecosystem. The aim is to enhance the translation of therapeutic candidates from early discovery to clinical trials, ultimately delivering lifesaving therapeutics.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
bit.bio and Ginkgo share the belief that their complementary products and services will enhance R&D outcomes for customers. Ginkgo’s clients will leverage ioCells for researching disease mechanisms and identifying therapeutic targets, with nearly 30 products currently available and more anticipated in 2024 and beyond.
Mark Kotter, CEO and founder of bit.bio, emphasized the collaborative nature of the partnership, noting Ginkgo’s ability to integrate diverse technologies to meet complex customer needs. The integration of ioCells into Ginkgo’s offering will significantly enhance experimental accuracy, providing customers with unrivaled cell function, scalability, and consistency.
Ginkgo’s role as a “systems integrator” within the biotech ecosystem ensures a unified experience for customers, with investments in infrastructure and tools aimed at facilitating access to various technical approaches. This approach enables customers to navigate a broader spectrum of capabilities rather than being limited by traditional constraints.